Afrin ecstro, spray 0.05% 15 ml

An alpha-adrenergic stimulant for topical use. It has a vasoconstrictor effect. Oxymetazoline causes vasoconstriction of mucous membranes of the nose, sinuses and Eustachian tube, which leads to reduction of their edema and release of nasal breathing in allergic and/or infectious inflammatory rhinitis (runny nose).

. Due to the presence of excipients in the composition of the medicine (microcrystalline cellulose and sodium carmellose and povidone-K29-32) Afrin® exro nasal spray does not leak from the nose and does not run down the throat, because after the introduction into the nasal passages the spray becomes more viscous and is held on the nasal mucosa more effectively than the standard water solution.

Based on published clinical studies, intranasal administration of an aroma composition similar to that of the drug containing levomenthol (also known as menthol), cineol (also known as eucalyptus) and camphor causes a temporary nasal mucosal cooling sensation through interaction with the trigeminal nerve receptors on the mucosal surface.

According to clinical studies, the drug starts working within 1 minute and the action lasts up to 12 hours.

Indications

Symptomatic treatment of rhinitis (runny nose) of allergic and/or infectious-inflammatory etiology, sinusitis, eustachitis, hay fever.

Pharmacological effect

Alpha adrenergic stimulant for topical use. Has a vasoconstrictor effect. Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and eustachian tube, which leads to a decrease in their swelling and the release of nasal breathing in allergic and/or infectious-inflammatory rhinitis (runny nose).

Due to the presence of excipients in the composition of the drug (microcrystalline cellulose and carmellose sodium and povidone-K29-32), Afrin® extra nasal spray does not flow out of the nose or down the throat, since after administration into the nasal passages the spray becomes more viscous and is retained on the mucous membranes of the nose more effectively than a standard aqueous solution.

Based on published clinical studies, intranasal administration of an aromatic composition similar to the formulation containing levomenthol (also known as menthol), cineole (also known as eucalyptus) and camphor causes a temporary cooling sensation in the nasal mucosa due to interaction with the cold receptors of the trigeminal nerve on the surface of the mucosa.

According to clinical studies, the drug begins to act within 1 minute and the effect lasts up to 12 hours.

Special instructions

With prolonged use (more than one week), symptoms of nasal congestion may recur. If it is necessary to continue treatment for more than 5 days, consultation with a doctor is necessary.

Avoid contact of the drug with the eyes. When used correctly and in recommended doses, the drug does not affect driving or operating machinery, however, if side effects such as dizziness occur, you should refrain from these activities.

Active ingredient

Oxymetazoline

Composition

Active substance:

oxymetazoline hydrochloride 0.5 mg.

Excipients:

microcrystalline cellulose and carmellose sodium (Avicel RC-591) 30 mg,

sodium hydrogen phosphate 0.975 mg,

sodium dihydrogen phosphate monohydrate 5.525 mg,

disodium edetate dihydrate 0.3 mg,

macrogol-1450 50 mg,

povidone-K29-32 30 mg,

benzyl alcohol 3 mg,

cineole 0.2 mg,

camphor 0.2 mg,

levomenthol 0.6 mg,

benzalkonium chloride solution 17% 1.471 mg,

polypropylene glycol 5 mg,

purified water q.s. up to 1 ml.

Contraindications

Hypersensitivity to sympathomimetic drugs, to any component of the drug, atrophic rhinitis, simultaneous use of monoamine oxidase inhibitors (including the period of 14 days after their discontinuation), children under 6 years of age.

With caution

Coronary artery disease, arrhythmias, chronic heart failure, severe atherosclerosis, arterial hypertension, hyperthyroidism, diabetes mellitus, chronic renal failure, angle-closure glaucoma, prostatic hyperplasia with clinical symptoms, pregnancy, lactation.

Side Effects

In general, the drug is well tolerated, and possible adverse events are usually mild and transient.

Transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing; increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disturbances.

With long-term use – tachyphylaxis, reactive hyperemia and atrophy of the nasal mucosa. Benzalkonium chloride, which is part of the drug, can cause local skin reactions.

Interaction

Slows down the absorption of local anesthetic drugs, lengthens their duration of action.

Concomitant use with other vasoconstrictor drugs increases the risk of side effects.

With simultaneous use of monoamine oxidase inhibitors (including a period of 14 days after their discontinuation), maprotiline and tricyclic antidepressants – increased blood pressure.

Overdose

In case of significant overdose or accidental ingestion, the following are possible: nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, increased blood pressure, shortness of breath, mental disorders, depression of the central nervous system (drowsiness, decreased body temperature, bradycardia, decreased blood pressure, respiratory arrest and coma).

Treatment: symptomatic; in case of accidental ingestion – gastric lavage, activated charcoal. Vasopressor drugs are contraindicated.

Storage conditions

At a temperature of 2–30 °C.

Shelf life

5 years

Manufacturer

Delpharm Montreal Inc., Canada